Literature DB >> 8016882

Organizing pneumonia following pulmonary transplantation and the development of obliterative bronchiolitis.

D S Milne1, A D Gascoigne, T Ashcroft, L Sviland, A J Malcolm, P A Corris.   

Abstract

Twelve patients receiving lung transplants between 1988 and 1992 who developed clinical and histological features of obliterative bronchiolitis (OB) were compared with a group of 13 patients with good stable lung function (FEV1 more than 80% of predicted). Histological features of 180 biopsies were studied from the first postoperative year in order to assess whether any were associated with the development of OB. Clinically and histologically defined pulmonary rejection occurring after the first month was more frequent in OB patients (P = 0.03). Organizing pneumonia that was associated with acute rejection but not with nonviral infection was also seen more frequently in OB patients (P = 0.003). When all available lung transplant recipients surviving beyond 18 months were included in analyses, organizing pneumonia in the first year was associated with an increased relative risk of developing OB of 2.26 (95% CL 1.19-4.29), and the occurrence of coexistent organizing pneumonia and pulmonary rejection gave a relative risk for OB of 6.33 (95% CL 1.61-24.94). An increased incidence of histologically defined organizing pneumonia in OB patients has not been described previously. Furthermore the coexistence of organizing pneumonia with pulmonary rejection in the first year posttransplantation is a strong predictive factor for the development of OB.

Entities:  

Mesh:

Year:  1994        PMID: 8016882

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

Review 1.  Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies.

Authors:  Andrew I R Scott; Linda D Sharples; Susan Stewart
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Post heart/lung transplantation management.

Authors:  P A Corris
Journal:  J R Soc Med       Date:  1995       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.